Multiple Myeloma Clinical Trials in Houston, Texas
36 recruitingHouston, Texas
Showing 1–20 of 36 trials
Recruiting
Phase 3
A Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)
Relapsed or Refractory Multiple Myeloma
Celgene810 enrolled266 locationsNCT05519085
Recruiting
Phase 1
A Phase I, Open-label, Multicenter Study to Evaluate the Safety, Tolerability, Cellular Kinetics, Immunogenicity, Pharmacodynamics, and Preliminary Efficacy of AZD0120 in Participants With Multiple Myeloma (DURGA-2)
Multiple Myeloma
AstraZeneca40 enrolled13 locationsNCT07073547
Recruiting
Phase 3
MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)
Multiple Myeloma
Pfizer492 enrolled274 locationsNCT06152575
Recruiting
Phase 2
Phase II Study of Salvage Radiation Treatment After B-cell Maturation Antigen Chimeric Antigen Receptor T-cell Therapy for Relapsed Refractory Multiple Myeloma
Multiple MyelomaPlasma Cell NeoplasmMalignant Plasma Cell Neoplasm
M.D. Anderson Cancer Center30 enrolled1 locationNCT05336383
Recruiting
Phase 1
A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma or Previously Treated Amyloid Light-chain (AL) Amyloidosis
Relapsed or Refractory Multiple MyelomaPreviously Treated Amyloid Light-chain (AL) Amyloidosis
Janssen Research & Development, LLC180 enrolled29 locationsNCT05652335
Recruiting
Phase 2
A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma
Multiple Myeloma
Janssen Research & Development, LLC157 enrolled31 locationsNCT07266441
Recruiting
Phase 2
TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
Advanced Solid TumorsMultiple MyelomaLymphoma, Non-Hodgkin
American Society of Clinical Oncology4,200 enrolled174 locationsNCT02693535
Recruiting
Phase 1Phase 2
ATRA and Carfilzomib in Plasma Cell Myeloma Patients
Multiple Myeloma
The Methodist Hospital Research Institute42 enrolled1 locationNCT06536413
Recruiting
Phase 3
A Study Comparing Anitocabtagene Autoleucel to Standard of Care Therapy in Participants With Relapsed/ Refractory Multiple Myeloma
Multiple Myeloma
Kite, A Gilead Company450 enrolled124 locationsNCT06413498
Recruiting
Phase 3
Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation
Multiple Myeloma
European Myeloma Network B.V.1,594 enrolled211 locationsNCT05243797
Recruiting
Phase 1Phase 2
A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)
Multiple MyelomaMyelodysplastic SyndromesLeukemia, Myeloid, Acute+1 more
Sumitomo Pharma America, Inc.606 enrolled104 locationsNCT04988555
Recruiting
Phase 3
A Study Comparing Talquetamab Plus Pomalidomide, Talquetamab Plus Teclistamab, and Elotuzumab, Pomalidomide, and Dexamethasone or Pomalidomide, Bortezomib, and Dexamethasone in Participants With Relapsed or Refractory Myeloma Who Have Received an Anti-CD38 Antibody and Lenalidomide
Multiple Myeloma
Janssen Research & Development, LLC795 enrolled242 locationsNCT06208150
Recruiting
Phase 3
A Study to Compare Iberdomide Maintenance Versus Lenalidomide Maintenance Therapy Following Autologous Stem Cell Transplant in Participants With Newly Diagnosed Multiple Myeloma
Multiple Myeloma
Bristol-Myers Squibb1,216 enrolled285 locationsNCT05827016
Recruiting
Phase 1Phase 2
Phase I/II Open Label Study of Belumosudil Mesylate Alone, and in Combination With Dexamethasone, in Patients With Relapsed/Refractory Multiple Myeloma
Multiple Myeloma
M.D. Anderson Cancer Center36 enrolled1 locationNCT06105554
Recruiting
Phase 2
Pre-transplant Purging and Post-transplant MRD-guided Maintenance Therapy With Elranatamab in Patients With High-risk Multiple Myeloma
Multiple MyelomaPost-transplant MRD-guided Maintenance TherapyPre-transplant Purging
M.D. Anderson Cancer Center40 enrolled1 locationNCT06207799
Recruiting
Phase 2
Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma
Multiple Myeloma
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company230 enrolled52 locationsNCT06297226
Recruiting
Phase 1Phase 2
A Study to Determine the Recommended Dose and Schedule, and Evaluate the Safety and Preliminary Efficacy of Mezigdomide in Combination With Elranatamab in Participants With Relapsed and/or Refractory Multiple Myeloma
Multiple Myeloma
Celgene62 enrolled22 locationsNCT06988488
Recruiting
Phase 1Phase 2
IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic Cancers
Multiple MyelomaNHLRefractory Non-Hodgkin Lymphoma+1 more
Indapta Therapeutics, INC.128 enrolled12 locationsNCT06119685
Recruiting
Not Applicable
Real World Insights During Treatment for Relapsed/Refractory Multiple Myeloma with Isatuximab
Multiple MyelomaRefractory Multiple Myeloma
Pack Health50 enrolled2 locationsNCT05053607
Recruiting
Phase 1Phase 2
Study to Assess Safety of HDP-101 in Patients With Relapsed Refractory Multiple Myeloma
Multiple MyelomaPlasma Cell Disorder
Heidelberg Pharma AG78 enrolled16 locationsNCT04879043